Clinical trial
A Randomized, Double-blind, Placebo-controlled, Single Ascending-Dose Phase Ia Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STSA-1201 Injection in Healthy Subjects
NCT05986877 is registered in ClinicalTrials.gov with Staidson (Beijing) Biopharmaceuticals Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, Single Ascending-Dose Phase Ia Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STSA-1201 Injection in Healthy Subjects
- Lead sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 4, 2023
- Completion date
- March 14, 2024
- Enrollment
- 44 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy